Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.
作者信息
Wamae Claire Njeri
机构信息
1School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
2Kenya Medical Research Institute, Nairobi, Kenya.
出版信息
Am J Trop Med Hyg. 2020 Jul;103(1):10-11. doi: 10.4269/ajtmh.20-0295. Epub 2020 May 26.
Abstract
摘要
相似文献
1
Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.非洲大规模药物管理与蠕虫防治经验：设想将伊维菌素用于治疗新型冠状病毒肺炎（SARS-CoV-2）
Am J Trop Med Hyg. 2020 Jul;103(1):10-11. doi: 10.4269/ajtmh.20-0295. Epub 2020 May 26.
2
Ivermectin: potential candidate for the treatment of Covid 19.伊维菌素：治疗新冠病毒病的潜在候选药物。
Braz J Infect Dis. 2020 Jul-Aug;24(4):369-371. doi: 10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28.
3
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?羟氯喹啉和伊维菌素：用于新冠病毒化学预防和治疗的协同组合？
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
4
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?基于宿主的治疗药物用于治疗2019冠状病毒病（COVID-19）：抗病毒机制与抗癌机制之间的联系？
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
5
Boosting the arsenal against COVID-19 through computational drug repurposing.通过计算药物重新利用增强对抗新冠病毒的手段。
Drug Discov Today. 2020 Jun;25(6):946-948. doi: 10.1016/j.drudis.2020.04.005. Epub 2020 Apr 15.
6
Repurposing antimalarials and other drugs for COVID-19.将抗疟药及其他药物重新用于治疗新冠肺炎。
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
7
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.标准剂量伊维菌素对重症 COVID-19 患者无效。
PLoS One. 2020 Nov 11;15(11):e0242184. doi: 10.1371/journal.pone.0242184. eCollection 2020.
8
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验（SAINT）评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力：一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
9
White paper on Ivermectin as a potential therapy for COVID-19.关于伊维菌素作为新冠病毒潜在疗法的白皮书。
Indian J Tuberc. 2020 Jul;67(3):448-451. doi: 10.1016/j.ijtb.2020.07.031.
10
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.COVID-19：分子靶点、药物再利用和新药发现途径。
Mem Inst Oswaldo Cruz. 2020 Oct 2;115:e200254. doi: 10.1590/0074-02760200254. eCollection 2020.
引用本文的文献
1
What Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of the SARS-CoV-2 Virus?非洲的 COVID-19 负担较低，尽管 SARS-CoV-2 病毒传播广泛，这是为什么？
Int J Environ Res Public Health. 2021 Aug 16;18(16):8638. doi: 10.3390/ijerph18168638.
2
The New Status of Parasitic Diseases in the COVID-19 Pandemic-Risk Factors or Protective Agents?新冠疫情下寄生虫病的新态势——风险因素还是保护因子？
J Clin Med. 2021 Jun 7;10(11):2533. doi: 10.3390/jcm10112533.
Zotero 插件